ASND

Ascendis Pharma A/S

Insider Trades

ActorHolding ValueLast TransactionAmountTransaction PriceCurrent Price
Smith Scott ThomasEVP & Chief Financial Officer
$956k4.4k shares
BuyJun 2, 2026
$21.9K100 shares
$219.00
--
Smith Scott ThomasEVP & Chief Financial Officer
$953k4.3k shares
BuyMay 29, 2026
$55.8K250 shares
$223.32
--
Bienaime Jean JacquesDirector
$134k600 shares
BuyMay 29, 2026
$44.8K200 shares
$223.76
--
Bienaime Jean JacquesDirector
$178k800 shares
BuyMay 29, 2026
$44.5K200 shares
$222.30
--
Bienaime Jean JacquesDirector
$201k900 shares
BuyMay 29, 2026
$22.4K100 shares
$223.50
--
Bienaime Jean JacquesDirector
$96k400 shares
BuyMay 26, 2026
$47.9K200 shares
$239.37
--

News

globenewswire.comPhase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidismglobenewswire.comJun 13seekingalpha.comTouchstone Mid Cap Growth Fund Q1 2026 Portfolio Reviewseekingalpha.comJun 12globenewswire.com5-Year Phase 2 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH in Adults with Hypoparathyroidismglobenewswire.comJun 11globenewswire.comAscendis to Showcase Advances in Treatment of Rare Endocrine Diseases at ENDO 2026globenewswire.comJun 8seekingalpha.comAscendis Pharma: Rare Endocrine Compounder Entering Growth Phase (Initiating Buy)seekingalpha.comMay 28